Data from Pharmawand - Curated by EPG Health - Date added 13 June 2019
The 24th Congress of the European Hematology Association (EHA) 2019 will take place in Amsterdam, The Netherlands, from the 13th to 16th June 2019.
The EHA Congress is a forum for original data, hematological innovation and evidence-based knowledge of primary clinical relevance. The congress also provides Satellite Symposia, Updates-in-Hematology and an exhibition organized by pharmaceutical companies, national and international non-profits.
Satellite symposia include: The changing face of cll treatment – moving with the times, higher hopes for high-risk acute myeloid leukemia?, molecular clinical assessment and monitoring of hematologic malignancies: b- and t-cell clonality, somatic hypermutation and mrd detection, defining a new paradigm for the management of acquired thrombotic thrombocytopenic purpura.
Visit our sponsored learning zones:
Chronic lymphocytic leukaemia – featuring EACCME accredited CME: 'Personalisation of chronic lymphocytic leukaemia (CLL) care' made by EPG Health, will award 1 European CME credit (EACCME) for successful completion.
Highlights from the 23rd EHA Congress are available and include: Updates on patient outcomes and safety with venetoclax, New findings on ibrutinib use in practice, Obinutuzumab plus chlorambucil, findings and implications for clinical practice and The clinical importance of ibrutinib resistance mutations.
Four slide presentations are available from the 59th ASH Annual Meeting and Exposition are available to view: Front-line treatment of CLL, Management of relapsed/ refractory CLL, Real-world data in CLL, Prognostic indicators in CLL.